INTRODUCTION {#s1}
============

Infantile fibrosarcoma (IFS) is a soft-tissue sarcoma that arises in the first year of life and is the most common non-rhabdomyosarcoma in this age group ([@MCS003376BENC24]). IFS typically manifests as a nontender, rapidly enlarging, circular, erythematous mass over the distal extremities ([@MCS003376BENC10]; [@MCS003376BENC1]). Histologically, IFS is characterized by fascicles of fairly uniform spindle-shaped cells with pale eosinophilic cytoplasm and high mitotic indices ([@MCS003376BENC3]). Classically, IFS is driven by the t(12;15)(p13;q25) translocation encoding the *ETV6--NTRK3* fusion protein, as also seen in congenital mesoblastic nephroma ([@MCS003376BENC14]; [@MCS003376BENC20]). Management consists of surgical resection, along with potentially neoadjuvant and adjuvant chemotherapy, with an overall 10-yr survival of ∼90%; unlike its adult counterparts, IFS is marked by a typically robust response to chemotherapy ([@MCS003376BENC18]). Although local recurrence is common, distant metastasis is relatively unusual, with the most common metastatic site being the lungs ([@MCS003376BENC3]; [@MCS003376BENC10]).

The neurotrophic receptor tyrosine kinase (*NTRK1-3*) family encodes tropomyosin receptor tyrosine kinase proteins (TRKA-C), which are involved in the regulation of neuronal cell proliferation, division, and differentiation ([@MCS003376BENC29]). Although initially described in colorectal cancer in 1986, TRK fusions are now being increasingly identified in a number of pediatric and adult malignancies and may be present in 1% of solid tumors ([@MCS003376BENC16]; [@MCS003376BENC7]). Given the prevalence of aberrant TRK signaling seen in a number of cancers, TRK inhibition represents an attractive therapeutic target. Crizotinib is a commercially available, oral tyrosine kinase inhibitor (TKI) that is approved by the FDA for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with ALK gene rearrangements ([@MCS003376BENC13]). In addition to ALK inhibition, crizotinib has shown activity against the NTRK pathway ([@MCS003376BENC25]). Although IFS is typically characterized by *ETV6--NTRK3* fusion, herein we present the case of a child with refractory, metastatic IFS whose tumor harbored a noncanonical *LMNA--NTRK1* fusion only identified by next-generation sequencing (NGS), who achieved a durable, complete response with crizotinib therapy.

CASE REPORT {#s2}
===========

Our patient was noted at birth to have a mass on her left forearm. As the patient was adopted, extended family history was unknown. At 13 d of life, the patient underwent biopsy of the lesion at an outside hospital, which revealed a low-grade spindle cell proliferation with fascicular arrangement and myxoid background infiltrating fatty tissue resembling fibromatosis ([Fig. 1](#MCS003376BENF1){ref-type="fig"}A,B). The cellularity was low to moderate with no significant atypia or mitotic figures noted. Lesional cells were negative for myogenin and MYOD1 and revealed weak staining with smooth muscle actin (SMA). The lesion was classified as fibromatosis with the differential diagnosis including lipofibromatosis, although the possibility of the biopsy representing the edge of an IFS could not be excluded. Fluorescence in situ hybridization (FISH) for sarcoma translocations, including t(12;15)(p13;q25), was performed and was negative. A repeat larger biopsy with further cytogenetic workup was recommended but not pursued. At that time, the decision was made to observe only.

![(*A*) Bland low-grade spindle cell proliferation infiltrating fat, 40×. (*B*) Tumor cells are round to ovoid with no significant atypia or mitotic figures. Focal myxoid areas present (arrows). (*C*) There is a spindle cell proliferation arranged in fascicles and sheets with some hemangiopericytoma-like vascular channels. (*D*) Lung with metastatic high-grade sarcoma.](MCS003376Ben_F1){#MCS003376BENF1}

At age 2, the left forearm mass began to enlarge, and the patient underwent repeat resection of \>95% of the mass. Pathology from this sample ([Fig. 1](#MCS003376BENF1){ref-type="fig"}C) showed a more cellular spindle cell proliferation arranged in fascicles and sheets with hemangiopericytoma-like vascular channels with focal necrosis and increased mitotic figures. The peripheral areas were less cellular and showed some myxoid background, similar to the initial biopsy, resembling fibromatosis. Tumor cells were positive with SMA; S100 and Ki-67 highlighted ∼10% positive nuclei. Desmin and epithelial membrane antigen were negative. The differential diagnosis at this stage included fibrosarcoma, spindle cell embryonal rhabdomyosarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, and synovial sarcoma. Myogenin and MYOD1 were negative. FISH and RT-PCR were again negative for common sarcoma translocations including ETV6--NTRK3. Overall, the pathology was characterized as high-grade spindle cell sarcoma, Pediatric Oncology Group (POG) grade 3/3, with a negative metastatic workup. The patient\'s parents elected not to proceed with amputation, and instead treatment began with six cycles of ifosfamide and doxorubicin according to ARST0332 (not on study), along with radiation for local control. Four months following completion of therapy, she developed recurrence at the original tumor site, along with a new mass on the left hand. The patient underwent amputation of the left proximal forearm, including both masses, with pathology demonstrating high-grade spindle cell sarcoma consistent with prior. The patient\'s parents deferred additional chemotherapy because the patient was disease-free. Four months after amputation, routine imaging revealed two nodules in the right lung, which were biopsied and revealed metastatic high-grade sarcoma ([Fig. 1](#MCS003376BENF1){ref-type="fig"}D). She underwent two cycles of gemcitabine and docetaxel and an additional six cycles of vincristine, actinomycin, and cyclophosphamide.

Approximately 10 mo following completion of treatment, she was found to have multiple recurrent pulmonary nodules, with the largest nodule identified in the inferior aspect of the right middle lobe and measuring 8 mm, but at least eight to10 nodules in both lungs ([Fig. 2](#MCS003376BENF2){ref-type="fig"}A,B). The patient was enrolled in the Peds-MiOncoSeq clinical sequencing study (UM-IRBMED HUM \#00056496) and underwent integrative sequencing as previously described ([@MCS003376BENC17]). Briefly, paired-end whole-exome libraries from the patient\'s original biopsy at diagnosis were matched with normal DNA and with transcriptome libraries, which were prepared and sequenced. Aligned exome and transcriptome sequences were analyzed to detect putative somatic mutations, insertions and deletions (indels), copy number alterations, gene fusions, and gene expression. The patient\'s parents provided informed consent and received pre-enrollment genetic counseling.

![Initial recurrence before crizotinib therapy: (*A*) a 0.63-mm slice thickness spiral axial image of the chest with intravenous iodinated contrast demonstrates a well-defined 8-mm right middle lobe lung nodule consistent with metastatic disease (arrow); and (*B*) an 8-mm maximum intensity projection (MIP) image with clear delineation of a 4.5-mm right lower lobe pulmonary metastasis in relationship to the pulmonary vasculature (arrow). Two months after initiation of crizotinib therapy: (*C*) a 0.63-mm spiral axial image with reduction in the size of the right middle lobe nodule (5.3 mm, arrow); and (*D*) a thin section axial image with decrease in size of the right lower lobe nodule, now 2.4 mm (arrow). Twenty-one months after initiation of crizotinib therapy: (*E*) residual linear scarring is noted in the region of the original right middle lobe metastasis; and (*F*) no clear residual nodule seen in the right lower lobe. Follow-up CT imaging (*G*, thin slice axial image; *H*, MIP image) demonstrates complete resolution of the nodules ∼12 mo after cessation of crizotinib therapy and ∼43 mo since its introduction.](MCS003376Ben_F2){#MCS003376BENF2}

Sequencing revealed a nonclassical *LMNA--NTRK1* fusion ([Fig. 3](#MCS003376BENF3){ref-type="fig"}). Patient was presented at our multidisciplinary precision oncology tumor board; because none of the specific NTRK inhibitors was available for clinical use in children at the time of discussion, a consensus recommendation was made to initiate treatment with crizotinib 200 mg BID. After ∼2 mo on crizotinib, a CT of the chest with intravenous contrast revealed a partial response with interval decrease in number and size of the pulmonary nodules, with the largest nodule in the right middle lobe having decreased in size to 5.3 mm ([Fig. 2](#MCS003376BENF2){ref-type="fig"}C,D). Treatment was tolerated well except for mild intermittent abdominal pain. A follow-up CT examination after 22 mo on therapy revealed complete resolution of the pulmonary nodules with residual scarring seen in both lungs including in the region of the prior right middle lobe nodule ([Fig. 2](#MCS003376BENF2){ref-type="fig"}E,F). Treatment with crizotinib was discontinued in May 2017, after ∼31 mo on treatment, because of parental request, and the patient remains in a durable complete response now \>18 mo off therapy ([Fig. 2](#MCS003376BENF2){ref-type="fig"}G,H).

![The *LMNA--NTRK1* fusion protein encodes a coiled-coil dimerization domain of LMNA (exon 2, NM_170707) fused to the tyrosine kinase domain of NTRK1 (exon 10, NM_001012331).](MCS003376Ben_F3){#MCS003376BENF3}

GENOMIC ANALYSES {#s3}
================

Upon referral to our institution, the patient was enrolled in the Peds-MiOncoSeq study. Tissue from the patient\'s original tumor resection was submitted in two blocks containing at least 60% tumor cells for integrative clinical exome (tumor and germline DNA) and transcriptome (tumor RNA) sequencing, as previously described ([@MCS003376BENC17]). Details of sequencing depth and quality are presented in [Table 1](#MCS003376BENTB1){ref-type="table"}, whereas other sequencing findings are summarized in [Table 2](#MCS003376BENTB2){ref-type="table"}. The results revealed copy loss at Chr 3q, copy gain at Chr 16, and homozygous deletion of *CDKN2A* and *CDKN2B* on Chr 9. Six total somatic mutations of unknown significance were identified affecting *STAG2*, *PKD1*, *FAM20A*, *HIST1H3I*, *RP11-614O9.3.1*, and *TMEM179*. Although the canonical *ETV6--NTRK3* fusion was not detected, a *LMNA--NTRK1* fusion was identified on both RNA sequencing and DNA-based hybridization capture. Correspondingly, increased RNA expression was noted of both NTRK1 and LMNA.

###### 

Sequencing details of normal and tumor exome and tumor transcriptome

  Exomes        Transcriptomes                                                       
  ------------- ---------------- ------ ------ ----- ----- ----- ----- ------------- ------
  110,706,636   85,801,852       96.7   93.6   187   140   4.2   3.5   107,818,594   91.0

PCR, polymerase chain reaction.

###### 

Somatic variants of potential significance identified in the patient

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                                   Genomic location                HGVS DNA ref.   HGVS protein ref.   Variant type          Predicted effect              dpSNP/dbVarID
  ------------------------------------------------------ ------------------------------- --------------- ------------------- --------------------- ----------------------------- ---------------
  Rearrangement analysis                                                                                                                                                         

   *LMNA--NTRK1*                                         5′-junction: Chr 1:156100565\   N/A             N/A                 Inversion             LMNA--NTRK1 in-frame fusion   N/A
                                                         3′-junction: Chr 1:156844697                                                                                            

  Copy number variations                                                                                                                                                         

   *CDKN2A*                                              Chr 9                           N/A             N/A                 Homozygous deletion   Deletion of CDKN2A            N/A

   *CDKN2B*                                              Chr 9                           N/A             N/A                 Homozygous deletion   Deletion of CDKN2B            N/A

   Chr 3q                                                Chr 3                           N/A             N/A                 Copy loss             Loss of 3q                    N/A

   Chr 16                                                Chr 16                          N/A             N/A                 Copy gain             Gain of 16                    N/A

  Single nucleotide variants (of unknown significance)                                                                                                                           

   *FAM20A*\                                             Chr 17:66596677                 c.131G\>A       p.Cys44Tyr          Substitution          Missense                      N/A
  NM_017565.3                                                                                                                                                                    

   *HIST1H3I*\                                           Chr 6:27839829                  c.265G\>T       p.Ala89Ser          Substitution          Missense                      N/A
  NM_003533.2                                                                                                                                                                    

   *ZNF595*\                                             Chr 4:87313                     c.1916dupA,     p.Asp639fs          Substitution          Frameshift                    rs60154095
  NM_182524.3                                                                                                                                                                    

   *TMEM179*\                                            Chr 14:105071002                c.77T\>C        p.Val26Ala          Substitution          Missense                      N/A
  NM_001286389.1                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DISCUSSION {#s4}
==========

Herein we present the case of a child with refractory, metastatic IFS harboring an unusual *LMNA--NTRK1* fusion, not detected by routine FISH studies, who was successfully treated with crizotinib. To our knowledge, this is the first publication reporting a complete and durable response of more than 48 mo to crizotinib therapy in a patient with metastatic, refractory IFS.

Rather than harboring the pathognomonic *ETV6--NTRK3* fusion, our patient presented with a nonclassical *LMNA--NTRK1* fusion. *LMNA* encodes proteins lamin A and lamin C, which are involved in the nuclear envelope structure. The *LMNA--NTRK1* fusion protein encodes a coiled-coil dimerization domain of LMNA fused to the tyrosine kinase domain of NTRK1. *LMNA--NTRK1* fusions have been implicated in a number of malignancies, including Spitz nevi ([@MCS003376BENC30]), colorectal cancer ([@MCS003376BENC22]), lung cancer ([@MCS003376BENC28]), soft-tissue sarcomas ([@MCS003376BENC9]; [@MCS003376BENC31]; [@MCS003376BENC15]), and a rare case of infantile-onset lipofibromatosis-like neural tumor ([@MCS003376BENC2]).

Within the past 2 years, there have been additional case reports of *LMNA--NTRK1* fusions in pediatric soft-tissue sarcomas and IFS. One recent article reported two pediatric soft-tissue sarcomas with similar fusions, including *LMNA--NTRK1* or *TPM3--NTRK1*, in which pathology revealed a consistent pattern of myopericytic and hemangiopericytic histologic features, along with high mitotic rates, similar to the pathologic description of the case presented herein ([@MCS003376BENC9]). In contrast to our patient, neither patient in their series had metastatic progression. *LMNA--NTRK1* fusion was additionally identified in a 6-yr-old with a forearm mass; however, histology revealed few mitotic figures without a hemangiopericytic appearance ([@MCS003376BENC15]). In a recent large study of pediatric tumor specimens, two cases harbored *LMNA--NTRK1* fusions ([@MCS003376BENC19]). Of the two patients with *LMNA--NTRK1* fusions, one was a 1-yr-old with metastatic fibrosarcoma, the other patient was a 14-yr-old with PNET. Similarly, in a recent case series of six infants with lesions resembling IFS without *ETV6--NTRK3* fusion, one of the patients tested positive for *LMNA--NTRK1* fusion ([@MCS003376BENC5]). Most notably, Wong et al. reported on a similar case of metastatic IFS that tested positive for *LMNA--NTRK1*, although pathology did not reveal a hemangiopericytic pattern as seen in our case and in the series by Florian et al. After progressing despite multiple chemotherapies, their patient was started on crizotinib and had a dramatic partial response to treatment ([@MCS003376BENC31]). Of note, as in our case presented here, coincident *CDKN2A* deletions have been found in a significant number of the above patients who harbor *NTRK1* fusions, including three of four cases ([@MCS003376BENC9]), two of four cases ([@MCS003376BENC19]), three of five cases ([@MCS003376BENC6]), and in Wong\'s case above ([@MCS003376BENC31]).

*NTRK* fusions are being increasingly implicated in a number of malignancies in both pediatric and adult patients, including pediatric high-grade glioma ([@MCS003376BENC32]), soft-tissue sarcomas ([@MCS003376BENC9]), secretory breast cancer ([@MCS003376BENC27]), and papillary thyroid cancer ([@MCS003376BENC11]), in addition to many other solid tumors ([@MCS003376BENC23]). The case presented herein fits nicely into the evolving landscape of noncanonical *NTRK* fusions, which are being increasingly identified in pediatric soft-tissue sarcomas. In a study of 2031 pediatric tumor specimens, *NTRK* fusions were identified in nine cases (0.44%), including three *ETV6--NTRK3*, one *TGF--NTRK3*, one *SQSTM1--NTRK1*, one *TPM3--NTRK1*, one *TPR1--NTRK1*, and two *LMNA--NTRK1* as cited above ([@MCS003376BENC19]). There have been three additional patients reported with IFS harboring *EML4--NTRK3* fusions rather than the classic *ETV6--NTRK3* fusion, as well ([@MCS003376BENC26]; [@MCS003376BENC4]; [@MCS003376BENC12]). Consistently, in a recent article of 10 patients with *ETV6--NTRK3* fusion-negative spindle cell sarcomas with pathology reminiscent of IFS, testing revealed one *EML4--NTRK3* fusion and one *TPM3--NTRK1* fusion ([@MCS003376BENC12]).

Crizotinib is an oral TKI, which has been shown to have in vitro activity against the *ETV6--NTRK3* fusion protein, along with specific inhibition of TRKA ([@MCS003376BENC25]; [@MCS003376BENC28]). Given the increasing awareness of aberrant TRK signaling in a wide number of malignancies, selective TRK inhibitors are currently in early-phase clinical trials, with positive initial results. The first published report centered on a targeted TRK inhibitor, larotrectinib (LOXO-101), which produced rapid response in an adult patient with soft-tissue sarcoma harboring the *LMNA--NTRK1* fusion ([@MCS003376BENC6]). Recently, a phase I trial of 55 adult and pediatric patients harboring TRK fusion-positive tumors showed significant and durable efficacy in patients of all ages, including seven patients with IFS ([@MCS003376BENC7]). Moreover, a recent study of five pediatric patients with locally advanced sarcomas with TRK fusions demonstrated partial response to neoadjuvant larotrectinib resulting in less extensive and morbid surgical resections ([@MCS003376BENC8]).

As our ability to develop effective targeted treatments continues to advance rapidly, so too does the need grow for adequate molecular characterization of each patient\'s tumor. It is becoming increasingly evident that aberrant NTRK signaling plays a vital role in mediating solid tumors in both pediatric and adult patients. Through NGS, we were able to identify and to target a noncanonical *LMNA--NTRK1* fusion protein in our patient, not detected by FISH or RT-PCR, and subsequently to induce a durable and complete response with crizotinib, despite our patient having previously failed multiple resections and chemotherapeutic agents. As NGS technology is not yet easily accessible to all patients, other research groups have published on the feasibility of using pan-Trk immunohistochemistry to identify *NTRK* rearrangements in pediatric mesenchymal cancers rather than relying on standard FISH and RT-PCR panels, which miss nonclassical *NTRK* rearrangements, as was the case initially for our patient ([@MCS003376BENC21]).

Given the growing recognition of *NTRK* fusions in a variety of tumors, especially soft-tissue sarcomas, further work will be required to characterize the histologic, molecular, and clinical signatures of such malignancies. Whether soft-tissue sarcomas of infancy harboring nonclassical *NTRK* fusions represent a distinct clinical entity from IFS showing the canonical *ETV6--NTRK3* fusion also remains to be further investigated. Although phase I trials of targeted TRK inhibitors show promise, the widespread clinical availability of such agents remains far off. In pediatric patients with soft-tissue sarcomas harboring *NTRK* fusions refractory to standard treatments, oral crizotinib may be a reasonable and effective therapeutic option for inducing complete and durable response while eagerly awaiting clinical deployment of selective TRK inhibitors.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

All somatic mutation information generated from this study has been uploaded to dbGaP (<https://www.ncbi.nlm.nih.gov/gap>) under accession number phs000673.v2.p1. The interpreted variants were deposited to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000864230.
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